Pharma Exclusives Pressreleases
Tezspire approved in the US for chronic rhinosinusitis with nasal polyps
Saturday, October 18, 2025AstraZeneca and Amgens Tezspire tezepelumab has been approved in the US for the addon maintenance treatment of adult and paediatric patients aged years and older with inadequately controlled chronic rhinosinusitis
Thermo Fisher Scientific to Accelerate Life Science Breakthroughs with OpenAI
Friday, October 17, 2025Thermo Fisher Scientific Inc the world leader in serving science announced plans to further increase the impact of Thermo Fishers proven growth strategy through the use of artificial intelligence AI with OpenAI
Thermo Fisher Scientific Fuels the Future of Multi-omics Research with the Launch of Next-Generation Microarray Solution
Thursday, October 16, 2025Thermo Fisher Scientific the world leader in serving science has introduced the Applied Biosystems SwiftArrayStudio Microarray Analyzer designed for fast and scalable sample analysis In conjunction with two new arrays
Bristol Myers Squibb Strengthens and Diversifies Cell Therapy Portfolio with Acquisition of Orbital Therapeutics
Friday, October 10, 2025Bristol Myers Squibb and Orbital Therapeuticstoday announced a definitive agreement under which BMS will acquire Orbital a privately held biotechnology company pioneering a new generation of RNA medicines that reprogram
Thermo Fisher Scientific Introduces New Molecular Microscope® Diagnostic System to Aid in Evaluation of Lung Transplant Rejection
Thursday, October 09, 2025Thermo Fisher Scientific the world leader in serving science has introduced a new laboratory developed test for posttransplant biopsy assessment designed to improve the detection of lung transplant rejection and injury
Lilly plans to build a new $6.5 billion facility to manufacture active pharmaceutical ingredients in Texas
Wednesday, September 24, 2025Eli Lilly and Company announced today that it plans to build a new billion manufacturing facility at Generation Park in Houston Texas This planned nextgeneration synthetic medicine active pharmaceutical product API facility the second of four new US...
Lexicon Pharmaceuticals Announces Update on Submission of Additional Data to U.S. FDA Supporting the Benefit-Risk Profile of Zynquista® in Type 1 Diabetes
Tuesday, September 23, 2025Lexicon Pharmaceuticals Inc today announced an update to the previous submission of additional clinical data to the US Food and Drug Administration FDA from ongoing thirdparty funded investigatorinitiated
Longeveron® to Attend Alliance for Regenerative Medicine’s Cell & Gene Meeting on the Mesa
Tuesday, September 23, 2025Longeveron Inca clinical stage biotechnology company developing cellular therapies for lifethreatening rare pediatric and chronic agingrelated conditions today announced that it will participate in the Alliance for Regenerative Medicines Cell Gene M...
Cybin Completes Enrollment in Phase 2 Study Evaluating CYB004 for the Treatment of Generalized Anxiety Disorder
Monday, September 08, 2025Cybin Inc a clinicalstage breakthrough neuropsychiatry company committed to advancing mental healthcare by developing new and innovative nextgeneration treatment options today announced completion of enrollment
Allergan Aesthetics Launches Campaign to Educate Consumers about Hyaluronic Acid (HA) Injectable Fillers
Wednesday, September 03, 2025Allergan Aesthetics an AbbVie company has launched the Naturally You with Injectable Hyaluronic Acid Fillers campaign aimed to providing clear factual education about HA injectable fillers
